Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pharvaris N.V. - Ordinary Shares
(NQ:
PHVS
)
25.46
-0.47 (-1.81%)
Streaming Delayed Price
Updated: 2:55 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
35,823
Open
25.99
Bid (Size)
25.25 (100)
Ask (Size)
25.58 (100)
Prev. Close
25.93
Today's Range
25.38 - 26.09
52wk Range
11.51 - 29.80
Shares Outstanding
33,816,459
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?
↗
December 09, 2025
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.
Via
The Motley Fool
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
↗
December 08, 2025
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
Via
The Motley Fool
Topics
Regulatory Compliance
Performance
YTD
+37.3%
+37.3%
1 Month
+0.0%
+0.0%
3 Month
+3.6%
+3.6%
6 Month
+42.2%
+42.2%
1 Year
+30.6%
+30.6%
More News
Read More
PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment
↗
December 03, 2025
Via
Stocktwits
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
December 03, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now
↗
December 02, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company
↗
November 29, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million
↗
November 20, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
↗
November 20, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Gets Booted in Latest Fund Update
↗
November 19, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock
↗
November 19, 2025
Via
The Motley Fool
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?
↗
November 18, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out
↗
November 18, 2025
Via
The Motley Fool
Why Bain Capital Is Selling Shares of This Biotech Stock Now
↗
November 18, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
November 10, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
October 23, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
This Uber Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
October 15, 2025
Via
Benzinga
Pharvaris NV (NASDAQ:PHVS) Reports Wider Q2 2025 Loss, Highlights Clinical Trial Progress
↗
August 12, 2025
Via
Chartmill
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 24, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
July 22, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Proposed Public Offering of Ordinary Shares
July 22, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
July 10, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
June 27, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
June 16, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Frequently Asked Questions
Is Pharvaris N.V. - Ordinary Shares publicly traded?
Yes, Pharvaris N.V. - Ordinary Shares is publicly traded.
What exchange does Pharvaris N.V. - Ordinary Shares trade on?
Pharvaris N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Pharvaris N.V. - Ordinary Shares?
The ticker symbol for Pharvaris N.V. - Ordinary Shares is PHVS on the Nasdaq Stock Market
What is the current price of Pharvaris N.V. - Ordinary Shares?
The current price of Pharvaris N.V. - Ordinary Shares is 25.46
When was Pharvaris N.V. - Ordinary Shares last traded?
The last trade of Pharvaris N.V. - Ordinary Shares was at 12/26/25 02:55 PM ET
What is the market capitalization of Pharvaris N.V. - Ordinary Shares?
The market capitalization of Pharvaris N.V. - Ordinary Shares is 860.97M
How many shares of Pharvaris N.V. - Ordinary Shares are outstanding?
Pharvaris N.V. - Ordinary Shares has 861M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
